AMRX vs. HRMY, SUPN, GPCR, AGIO, TARO, AVDL, PTGX, DVAX, SDGR, and SNDX
Should you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include Harmony Biosciences (HRMY), Supernus Pharmaceuticals (SUPN), Structure Therapeutics (GPCR), Agios Pharmaceuticals (AGIO), Taro Pharmaceutical Industries (TARO), Avadel Pharmaceuticals (AVDL), Protagonist Therapeutics (PTGX), Dynavax Technologies (DVAX), Schrödinger (SDGR), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical preparations" industry.
Harmony Biosciences (NASDAQ:HRMY) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership.
Harmony Biosciences presently has a consensus target price of $40.63, indicating a potential upside of 38.56%. Amneal Pharmaceuticals has a consensus target price of $7.31, indicating a potential upside of 24.57%. Given Amneal Pharmaceuticals' higher probable upside, research analysts clearly believe Harmony Biosciences is more favorable than Amneal Pharmaceuticals.
Harmony Biosciences has higher earnings, but lower revenue than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.
Harmony Biosciences has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.
Harmony Biosciences received 33 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Amneal Pharmaceuticals an outperform vote while only 59.70% of users gave Harmony Biosciences an outperform vote.
86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 30.8% of Harmony Biosciences shares are held by insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Harmony Biosciences has a net margin of 22.16% compared to Harmony Biosciences' net margin of -3.51%. Harmony Biosciences' return on equity of 126.04% beat Amneal Pharmaceuticals' return on equity.
In the previous week, Amneal Pharmaceuticals had 3 more articles in the media than Harmony Biosciences. MarketBeat recorded 8 mentions for Amneal Pharmaceuticals and 5 mentions for Harmony Biosciences. Amneal Pharmaceuticals' average media sentiment score of 1.24 beat Harmony Biosciences' score of 0.47 indicating that Harmony Biosciences is being referred to more favorably in the media.
Summary
Harmony Biosciences beats Amneal Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Amneal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amneal Pharmaceuticals Competitors List
Related Companies and Tools
